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Reply to the letter from Drs David and Sobrinho-Simoes
Sir - We thank Drs David and Sobrinho-Simoes for their
interest in our article. Tenascin is a multifunctional
glycoprotein participating in an integral part of the normal
matrix, inflammation and embryogenesis. Tenascin was found
to be immunohistochemically expressed in the muscularis
mucosae or muscularis propria of normal tissue in both the
stomach (Ikeda et al., 1995) and colon (Riedl et al., 1992;
Sakai et al., 1993), as well as in inflammatory lesions of the
colon (Riedl et al., 1992). However, in these tissues tenascin
was expressed only weakly or moderately. Tenascin is also
produced during wound healing (Mackie et al., 1987), and
the granulation tissue of peptic ulcers, which was not
evaluated in this study, may also induce the production of
tenascin. As suggested by David and Sobrinho-Simoes, the
expression of tenascin in non-cancerous lesions still needs to
be analysed. There is also increasing evidence that tenascin
plays an important role in the oncofetal potential such as that
seen in tumour invasion or metastasis. Tenascin is induced by
transforming growth factor beta (TGF-fl) (Chiquet-Ehnrs-
mann et al., 1989), and is composed of paracentral epidermal
growth factor (EGF)-like repeats (Jones et al., 1988).
Previous studies have consistently reported that tenascin
was markedly expressed in the tissue of malignant tumours
(Howeedy et al., 1990; Riedl et al., 1992; Sakai et al.. 1993).
Tenascin most likely cannot be used as an all-or-nothing
marker for malignant tumours. However, the different
degrees of tenascin expression may be useful as a stromal
marker for the early detection of malignant disease including
gastric cancer.
Yoichi Ikeda
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Gonadal atrophy as a cause of thymic hyperplasia after chemotherapy
Sir-In recent years there have been at least 18 reports
observing thymic hyperplasia in patients recovering from
combination chemotherapy for cancer without obvious
explanation (for review see Kissin, 1987), mostly young
patients with testis cancer or lymphoma.
Reports of regeneration of the thymus in castrated rabbits
(for review see Grossman, 1985) and observation of a
lymphocytosis in patients with prostate cancer treated by
medical castration (Oliver et al., 1995) prompted an
investigation into gonadal function in germ cell cancer
patients who developed thymic hyperplasia post chemother-
apy. This letter reports the preliminary results.
Computerised tomography (CT) scans from all patients
referred to one of us (PS) with metastatic germ cell cancer
who completed treatment with cisplatin-based cytotoxic
chemotherapy between 1980 and 1990 have been reviewed
with particular attention to assessing the degree of thymic
hyperplasia in the post-chemotherapy period. Any patient in
whom obvious enlargement was visible was considered to be
positive. There was little difficulty in recognising the shadow.
As part of an assessment of effect of treatment on fertility
all patients had serial readings of luteinising hormone (LH).
recorded before treatment, at 3 months after starting
treatment and at every attendance thereafter during the
following 5 years.
During the 10 year period under review, 236 patients were
entered into departmental studies. Review of CT scans
revealed 23 with thymic enlargement, three of whom had
the nature of the swelling confirmed at thoracotomy (Figure
1).
Four of 23 patients with thymic hyperplasia and only 1 of
37 disease extent- and age-matched germ cell cancer patient
controls selected randomly for hormone studies from the 199
without thymic hyperplasia had undergone bilateral orchid-
ectomy before treatment. Table I summarises the differences
in hormone estimations and demonstrates there is a
statistically significant increase in LH level in the group
with thymic hyperplasia.
The incidence of thymic hyperplasia in this series of testis
cancer patients (23,236) confirms the report of Kissin et al.